• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

T细胞同种异体反应性的特异性

Specificity of T-cell alloreactivity.

作者信息

Felix Nathan J, Allen Paul M

机构信息

Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri 63110, USA.

出版信息

Nat Rev Immunol. 2007 Dec;7(12):942-53. doi: 10.1038/nri2200.

DOI:10.1038/nri2200
PMID:18007679
Abstract

T-cell alloreactivity is a well-established phenomenon, but its molecular basis has remained enigmatic. Although there are differences between T-cell recognition of conventional and allogeneic antigens, it has become increasingly clear that they share many similarities. Recent insights into the specificity of the T-cell receptor (TCR) for peptide and the seeming intrinsic affinity of the TCR for the surface of the MHC molecule have provided a better understanding of how the TCR and peptide-MHC complexes interact. Here, we highlight the similarities and differences between conventional and allogeneic recognition of TCR-peptide-MHC complexes, and discuss how our view of allorecognitionhas changed, as well as the implications for TCR specificity and T-cell development.

摘要

T细胞同种异体反应性是一种已被充分证实的现象,但其分子基础一直不明。尽管T细胞对传统抗原和同种异体抗原的识别存在差异,但越来越明显的是,它们有许多相似之处。最近对T细胞受体(TCR)对肽的特异性以及TCR对MHC分子表面看似内在亲和力的深入了解,使人们对TCR与肽-MHC复合物如何相互作用有了更好的理解。在这里,我们强调了TCR-肽-MHC复合物的传统识别与同种异体识别之间的异同,并讨论了我们对同种异体识别的看法是如何改变的,以及对TCR特异性和T细胞发育的影响。

相似文献

1
Specificity of T-cell alloreactivity.T细胞同种异体反应性的特异性
Nat Rev Immunol. 2007 Dec;7(12):942-53. doi: 10.1038/nri2200.
2
Allogeneic core amino acids of an immunodominant allopeptide are important for MHC binding and TCR recognition.免疫显性异源肽的同种异体核心氨基酸对于MHC结合和TCR识别很重要。
Hum Immunol. 2004 Aug;65(8):817-25. doi: 10.1016/j.humimm.2004.05.007.
3
The CDR3 regions of an immunodominant T cell receptor dictate the 'energetic landscape' of peptide-MHC recognition.免疫显性T细胞受体的互补决定区3(CDR3)区域决定了肽-主要组织相容性复合体识别的“能量格局”。
Nat Immunol. 2005 Feb;6(2):171-80. doi: 10.1038/ni1155. Epub 2005 Jan 9.
4
Predicting interactions between T cell receptors and MHC-peptide complexes.预测 T 细胞受体与 MHC-肽复合物之间的相互作用。
Mol Immunol. 2011 Jan;48(4):553-62. doi: 10.1016/j.molimm.2010.10.014. Epub 2010 Nov 23.
5
Alloreactivity is limited by the endogenous peptide repertoire.同种异体反应受内源性肽库的限制。
Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3695-700. doi: 10.1073/pnas.1017015108. Epub 2011 Feb 14.
6
Two-step binding mechanism for T-cell receptor recognition of peptide MHC.T细胞受体识别肽-MHC的两步结合机制。
Nature. 2002 Aug 1;418(6897):552-6. doi: 10.1038/nature00920.
7
Molecular modeling of a T-cell receptor bound to a major histocompatibility complex molecule: implications for T-cell recognition.与主要组织相容性复合体分子结合的T细胞受体的分子建模:对T细胞识别的影响。
Protein Sci. 1995 Sep;4(9):1708-17. doi: 10.1002/pro.5560040906.
8
T cell allorecognition and MHC restriction--A case of Jekyll and Hyde?T细胞同种异体识别与MHC限制——杰基尔与海德的案例?
Mol Immunol. 2008 Feb;45(3):583-98. doi: 10.1016/j.molimm.2006.05.018. Epub 2007 Sep 14.
9
T cell receptor crossreactivity as a general property of T cell recognition.T细胞受体交叉反应性作为T细胞识别的一个普遍特性。
Mol Immunol. 2004 Feb;40(14-15):1009-17. doi: 10.1016/j.molimm.2003.11.003.
10
Degenerate recognition of T cell epitopes: impact of T cell receptor reserve and stability of peptide:MHC complexes.T细胞表位的简并识别:T细胞受体储备及肽:主要组织相容性复合体复合物稳定性的影响
Mol Immunol. 2004 Feb;40(14-15):1019-25. doi: 10.1016/j.molimm.2003.11.004.

引用本文的文献

1
Chemokine gradients spare graft endothelium from CD8+ T cell-mediated injury during allograft rejection.趋化因子梯度在同种异体移植排斥反应期间使移植血管内皮免受CD8 + T细胞介导的损伤。
J Clin Invest. 2025 Jul 15;135(14). doi: 10.1172/JCI193454.
2
Allogeneic Stem Cell Transplantation: The Relevance of Conditioning Regime Intensity for Myelodysplastic Syndromes (MDS).异基因干细胞移植:预处理方案强度对骨髓增生异常综合征(MDS)的相关性
Curr Oncol. 2025 May 30;32(6):319. doi: 10.3390/curroncol32060319.
3
Occlusion of TCR binding to HLA-A*11:01 by a non-pathogenic human alloantibody.
一种非致病性人类同种异体抗体对TCR与HLA - A*11:01结合的阻断作用。
Cell Mol Life Sci. 2025 Feb 26;82(1):94. doi: 10.1007/s00018-025-05614-y.
4
Allogeneic chimeric antigen receptors (CARs) as an "off-the-shelf" therapy in multiple myeloma.同种异体嵌合抗原受体(CARs)作为多发性骨髓瘤的一种“现成可用”疗法。
Immunotherapy. 2025 Feb;17(3):211-222. doi: 10.1080/1750743X.2025.2461987. Epub 2025 Feb 17.
5
A self-activated and protective module enhances the preclinical performance of allogeneic anti-CD70 CAR-T cells.一种自我激活和保护模块可增强同种异体抗CD70嵌合抗原受体T细胞(CAR-T细胞)的临床前性能。
Front Immunol. 2025 Jan 17;15:1531294. doi: 10.3389/fimmu.2024.1531294. eCollection 2024.
6
The Evolving T Cell Receptor Recognition Code: The Rules Are More Like Guidelines.不断演变的T细胞受体识别密码:规则更像是指导方针。
Immunol Rev. 2025 Jan;329(1):e13439. doi: 10.1111/imr.13439.
7
Managing allorejection in off-the-shelf CAR-engineered cell therapies.管理现成的嵌合抗原受体工程化细胞疗法中的同种异体排斥反应。
Mol Ther. 2024 Nov 26. doi: 10.1016/j.ymthe.2024.11.035.
8
Regenerative medicine in cardiovascular disease.心血管疾病中的再生医学
Regen Ther. 2024 Oct 5;26:859-866. doi: 10.1016/j.reth.2024.09.004. eCollection 2024 Jun.
9
Editorial: Emerging talents in alloimmunity and transplantation: 2022.社论:同种免疫与移植领域的新兴人才:2022年
Front Immunol. 2024 Mar 15;15:1393026. doi: 10.3389/fimmu.2024.1393026. eCollection 2024.
10
Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessment.标准抗癌药物和常用伴随药物的免疫肿瘤学效应:体外评估。
BMC Pharmacol Toxicol. 2024 Mar 5;25(1):25. doi: 10.1186/s40360-024-00746-6.